RecruitingNCT06828887
LV232 dose study for major depression
About this title
Read the official source — NCT06828887Medication studyAges 18–65China
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- ShanghaiSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 3, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 400
- Sponsor
- Vigonvita Life Sciences
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06828887
- Official title
Show the full official title
Multicenter,Randomized,Double-blind,Placebo,Parallel-controlled,Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of Major Depressive Disorder (MDD)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Shanghai
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vigonvita Life Sciences.
Does this study involve medication?
Yes. The study involves medication, including LV232 40mg, LV232 60mg, Escitalopram and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
